research Protein kinase C is a key target for attenuation of Leigh syndrome by rapamycin
Rapamycin may help treat Leigh syndrome by targeting protein kinase C.
Search
for
Sort by
Research
30-60 / 1000+ results 
research Janus kinase inhibitors for alopecia areata: a review of clinical data
JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
research Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.
research Protein Kinase C Epsilon Signals Ultraviolet Light‐induced Cutaneous Damage and Development of Squamous Cell Carcinoma Possibly Through Induction of Specific Cytokines in a Paracrine Mechanism¶
Protein kinase C epsilon may promote skin cancer development after UV exposure by affecting nearby cells.
research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research Janus kinase inhibitors for alopecia areata: A narrative review
Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
research Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
JAK inhibitors show promise for treating various skin diseases.
research Janus Kinase inhibitors in dermatology: a review
JAK inhibitors effectively treat skin conditions and topical forms are safer.
research Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
research The role of janus kinases in the treatment of autoimmune skin diseases
Janus kinase inhibitors show promise in treating autoimmune skin diseases.
research The Role of Janus Kinase Inhibitors in Dermatology
Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.
research Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
research 455 Beyond Immunity: TEC and JAK3 Kinase Activation in Melanocytes Drives Inflammation in Vitiligo
TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.
research 0935 Unravelling the role of JAK3/TEC kinase signalling with ritlecitinib in alopecia areata lesional skin and alopecia areata-induced human hair follicles ex vivo
Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
research Perspectives of Chinese Adult Patients with Alopecia Areata on Janus Kinase Inhibitors Therapy: A Qualitative Analysis Based on Social Media Platforms
Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.
research P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib
Some leukemia treatments can cause skin reactions similar to keratosis pilaris.
research Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
research Protein Kinase C Downregulation upon Rapamycin Treatment Attenuates Neuroinflammation and Mitochondrial Disease
Rapamycin treatment helps reduce brain inflammation and symptoms of mitochondrial disease by blocking specific pathways in mice.
research Characterisation, genomic organisation, expression and function of the mEphA1 receptor Tyrosine Kinase
mEphA1 receptor tyrosine kinase is important for skin and hair development and may play a role in certain diseases.
research Overexpression of protein kinase C-α in the epidermis of transgenic mice results in striking alterations in phorbol ester-induced inflammation and COX-2, MIP-2 and TNF-α expression but not tumor promotion
Overexpressing PKCα in mice skin increases inflammation but doesn't affect tumor growth.
research Transgenic mice overexpressing protein kinase C epsilon in their epidermis exhibit reduced papilloma burden but enhanced carcinoma formation after tumor promotion.
Overexpressing PKCepsilon in mice reduces papillomas but increases carcinomas.
research Protein kinase Cepsilon is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor-alpha ectodomain shedding and the development of metastatic squamous cell carcinoma in protein kinase Cepsilon transgenic mice.
Overexpression of PKCepsilon leads to increased TNFalpha, promoting metastatic squamous cell carcinoma in mice.
research Activation of Cutaneous Protein Kinase Cα Induces Keratinocyte Apoptosis and Intraepidermal Inflammation by Independent Signaling Pathways
Activating PKCα in skin causes cell death and inflammation through different pathways.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
research Tyrosine kinase inhibition and grey hair
Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing
Frontal fibrosing alopecia is linked to increased immune system activity and reduced stem cells, suggesting early treatment targeting this pathway might prevent hair follicle damage.